PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis = PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis

다국어 초록 (Multilingual Abstract)

Phosphoinositide 3-kinase (PI3K) is considered as a promising therapeutic target for rheumatoid arthritis (RA) because of its involvement in inflammatory processes. However, limited studies have reported the involvement of PI3KC2γ in RA, and the underlying mechanism remains largely unknown. Therefore, we investigated the role of PI3KC2γ as a novel therapeutic target for RA and the effect of its selective inhibitor, PBT-6. In this study, we observed that PI3KC2γ was markedly increased in the synovial fluid and tissue as well as the PBMCs of patients with RA. PBT-6, a novel PI3KC2γ inhibitor, decreased the cell growth of TNFmediated synovial fibroblasts and LPS-mediated macrophages. Furthermore, PBT-6 inhibited the PI3KC2γ expression and PI3K/ AKT signaling pathway in both synovial fibroblasts and macrophages. In addition, PBT-6 suppressed macrophage migration via CCL2 and osteoclastogenesis. In CIA mice, it significantly inhibited the progression and development of RA by decreasing arthritis scores and paw swelling. Three-dimensional micro-computed tomography confirmed that PBT-6 enhanced the joint structures in CIA mice. Taken together, our findings suggest that PI3KC2γ is a therapeutic target for RA, and PBT-6 could be developed as a novel PI3KC2γ inhibitor to target inflammatory diseases including RA.

참고문헌 (Reference)

1 Vitale, R. F., "The role of tumor necrosis factor-alpha(TNF-alpha)in bone resorption present in middle ear cholesteatoma" 73 : 117-121, 2007

2 Hofbauer, L. C., "The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis" 44 : 253-259, 2001

3 Foster, F. M., "The phosphoinositide(PI)3-kinase family" 116 : 3037-3040, 2003

4 McInnes, I. B., "The pathogenesis of rheumatoid arthritis" 365 : 2205-2219, 2011

5 Udagawa, N., "The mechanism of osteoclast differentiation from macrophages : possible roles of T lymphocytes in osteoclastogenesis" 21 : 337-343, 2003

6 Rosengren, S., "The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon" 71 : 440-447, 2012

7 Zheng, Y., "TNF alpha promotes Th17 cell differentiation through IL-6 and IL-1beta produced by monocytes in rheumatoid arthritis" 2014 : 385352-, 2014

8 Haringman, J. J., "Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis" 64 : 834-838, 2005

9 Mulherin, D., "Synovial tissue macrophage populations and articular damage in rheumatoid arthritis" 39 : 115-124, 1996

10 Huber, L. C., "Synovial fibroblasts: key players in rheumatoid arthritis" 45 : 669-675, 2006

11 Wymann, M. P., "Structure and function of phosphoinositide 3-kinases" 1436 : 127-150, 1998

12 Li, Z., "Roles of PLC-beta2 and-beta3 and PI3Kgamma in chemoattractant-mediated signal transduction" 287 : 1046-1049, 2000

13 Kapoor, M., "Role of proinflammatory cytokines in the pathophysiology of osteoarthritis" 7 : 33-42, 2011

14 Brennan, F. M., "Role of proinflammatory cytokines in rheumatoid arthritis" 20 : 133-147, 1998

15 Jones, D. H., "Role of RANKL and RANK in bone loss and arthritis" 61 (61): ii32-ii39, 2002

16 Yu, J., "Regulation of the p85/p110alpha phosphatidylinositol 3’-kinase. Distinct roles for the nterminal and c-terminal SH2 domains" 273 : 30199-30203, 1998

17 Divecha, N., "Phospholipid signaling" 80 : 269-278, 1995

18 Wetzker, R., "Phosphoinositide 3-kinases as targets for therapeutic intervention" 10 : 1915-1922, 2004

19 O’Farrell, F., "Phosphoinositide 3-kinases as accelerators and brakes of autophagy" 280 : 6322-6337, 2013

20 Vanhaesebroeck, B., "Phosphoinositide 3-kinases : a conserved family of signal transducers" 22 : 267-272, 1997

21 Lloyd, G., "Phobias complicating treatment of uterine carcinoma" 4 : 440-, 1975

22 Frisell, T., "Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics" 77 : 650-657, 2018

23 Kim, D. I., "PI3K-γ inhibition ameliorates acute lung injury through regulation of IκBα/NF-κB pathway and innate immune responses" 32 : 340-351, 2012

24 Braccini, L., "PI3K-C2gamma is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling" 6 : 7400-, 2015

25 Harris, S. J., "PI3K isoforms as drug targets in inflammatory diseases : lessons from pharmacological and genetic strategies" 10 : 1151-1162, 2009

26 Rommel, C., "PI3K delta and PI3K gamma : partners in crime in inflammation in rheumatoid arthritis and beyond? Nat" 7 : 191-201, 2007

27 Boyle, D. L., "Novel phosphoinositide 3-kinase δ,γ inhibitor: potent antiinflammatory effects and joint protection in models of rheumatoid arthritis" 348 : 271-280, 2014

28 Burmester, G. R., "Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?" 40 : 5-18, 1997

29 Iwamoto, T., "Molecular aspects of rheumatoid arthritis : chemokines in the joints of patients" 275 : 4448-4455, 2008

30 Udalova, I. A., "Macrophage heterogeneity in the context of rheumatoid arthritis" 12 : 472-485, 2016

31 Tabas, I., "Macrophage death and defective inflammation resolution in atherosclerosis" 10 : 36-46, 2010

32 Takayanagi, H., "Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis" 43 : 259-269, 2000

33 Romas, E., "Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis" 30 : 340-346, 2002

34 Weitzmann, M. N., "Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines" 96 : 1873-1878, 2000

35 Yu, W., "Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl)contributes to impaired chemotaxis and aberrant homing of leukemic cells" 51 : 1098-1107, 2010

36 Ho, L. K., "Identification of four novel human phosphoinositide 3-kinases defines a multi-isoform subfamily" 235 : 130-137, 1997

37 Gillespie, J., "Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients" 64 : 418-422, 2012

38 Curtis, M. J., "Experimental design and analysis and their reporting : new guidance for publication in BJP" 172 : 3461-3471, 2015

39 Koch, A. E., "Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis" 90 : 772-779, 1992

40 Bottini, N., "Duality of fibroblast-like synoviocytes in RA : passive responders and imprinted aggressors" 9 : 24-33, 2013

41 Reddy, V. A., "Dihydrofolate reductase from soybean seedlings. Characterization of the enzyme purified by affinity chromatography" 174 : 675-683, 1976

42 Freitag, A., "Development of first lead structures for phosphoinositide 3-kinase-C2gamma inhibitors" 58 : 212-221, 2015

43 Del Prete, A., "Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice" 23 : 3505-3515, 2004

44 McInnes, I. B., "Cytokines in the pathogenesis of rheumatoid arthritis" 7 : 429-442, 2007

45 Jia, Q., "Cucurbitacin E inhibits TNF-α-induced inflammatory cytokine production in human synoviocyte MH7A cells via suppression of PI3K/Akt/NF-κB pathways" 29 : 884-890, 2015

46 Mukaida, N., "Cooperative interaction of nuclear factor-kappa B-and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines" 265 : 21128-21133, 1990

47 Yokota, K., "Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo" 66 : 121-129, 2014

48 Rasmussen, A. L., "Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis" 430 : 43-52, 2012

49 Hirsch, E., "Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation" 287 : 1049-1053, 2000

50 Katso, R., "Cellular function of phosphoinositide 3-kinases:implications for development, homeostasis, and cancer" 17 : 615-675, 2001

51 Pap, T., "Cartilage damage in osteoarthritis and rheumatoid arthritis--two unequal siblings" 11 : 606-615, 2015

52 Camps, M., "Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis" 11 : 936-943, 2005

53 Asagiri, M., "Autoamplification of NFATc1 expression determines its essential role in bone homeostasis" 202 : 1261-1269, 2005

54 Min, D. J., "Augmented production of chemokines by the interaction of type II collagen-reactive T cells with rheumatoid synovial fibroblasts" 50 : 1146-1155, 2004

55 Nishimoto, N., "Anti-interleukin 6 receptor antibody treatment in rheumatic disease" 59 (59): i21-i27, 2000

56 Clavel, C., "Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA" 75 : 2184-2191, 2016

57 Pirola, L., "Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling" 276 : 21544-21554, 2001